Tempest Therapeutics Inc
TPST10.130USD
+0.120+1.20%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
44.96MMarket Cap
LossP/E TTM
More Details of Tempest Therapeutics Inc Company
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Company Info
Ticker SymbolTPST
Company nameTempest Therapeutics Inc
IPO dateOct 04, 2012
CEO- -
Number of employees24
Security typeOrdinary Share
Fiscal year-endOct 04
Address2000 Sierra Point Parkway
CityBRISBANE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94005
Phone14157988589
Websitehttps://www.tempesttx.com/
Ticker SymbolTPST
IPO dateOct 04, 2012
CEO- -
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 22
Updated: Fri, Aug 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
6.23%
Versant Ventures
3.67%
Tang Capital Management, LLC
3.13%
The Vanguard Group, Inc.
3.03%
BlackRock Institutional Trust Company, N.A.
0.88%
Other
83.06%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
6.23%
Versant Ventures
3.67%
Tang Capital Management, LLC
3.13%
The Vanguard Group, Inc.
3.03%
BlackRock Institutional Trust Company, N.A.
0.88%
Other
83.06%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
7.02%
Investment Advisor
5.00%
Venture Capital
3.67%
Hedge Fund
3.13%
Individual Investor
0.12%
Bank and Trust
0.03%
Research Firm
0.01%
Other
81.01%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
71
462.14K
11.78%
-326.50K
2025Q1
72
466.15K
11.99%
-315.34K
2024Q4
74
6.85M
15.70%
-2.07M
2024Q3
64
6.40M
25.40%
-2.51M
2024Q2
60
6.46M
29.08%
-2.26M
2024Q1
57
6.17M
27.79%
-2.56M
2023Q4
58
6.52M
33.89%
-1.52M
2023Q3
54
8.53M
66.99%
-219.33K
2023Q2
55
8.95M
101.95%
+3.83M
2023Q1
67
8.34M
99.34%
+3.30M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Versant Ventures
269.77K
6.87%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
22.91K
0.58%
+9.36K
+69.07%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
42.91K
1.09%
+742.00
+1.76%
Mar 31, 2025
Geode Capital Management, L.L.C.
33.33K
0.85%
+6.08K
+22.32%
Mar 31, 2025
Fidelity Management & Research Company LLC
33.23K
0.85%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
24.90K
0.63%
+11.25K
+82.43%
Mar 31, 2025
Brady (Stephen R)
3.61K
0.09%
+46.00
+1.29%
Apr 09, 2025
Morgan Stanley Smith Barney LLC
2.06K
0.05%
-123.00
-5.64%
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Date
Type
Ratio
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
